NL-OMON40398已完成4 期
Anidulafungin pharmacokinetics given as a single intravenous dose to obese patients (ADOPT). - ADOPT
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patient has a BMI >=40 kg/m2 and is undergoing bariatric surgery.
- •2. Subject is at least 18 years of age on the day of screening.
- •3. If subject is female: neither pregnant, nor able to become pregnant and is not nursing an infant.
- •4. Subject or legal representatives are able and willing to sign the Informed Consent before screening evaluations.
排除标准
- •1. Documented history of sensitivity to medicinal products or excipients similar to those found in the anidulafungin preparation.
- •2. History of or current abuse of drugs, alcohol or solvents.
- •3. Inability to understand the nature of the trial and the procedures required.
研究者
相似试验
进行中（未招募）
不适用
The pharmacokinetics of anidulafungin during continuous venovenous hemofiltratiointensive care patients with suspected or proven fungal infection, who undergo hemofiltrationMedDRA version: 9.1Level: LLTClassification code 10042941Term: Systemic fungal infection NOSEUCTR2008-007753-12-ATMUW, Universitätsklinik für Innere Medizin I, Abteilung für Infektionskrankheiten und Tropenmedizin
已完成
4 期
Pharmacokinetics of anidulafungin in critically ill patients with invasive candidiasisinvasive candidiasisinvasive fungal infection10017528NL-OMON32922niversitair Medisch Centrum Groningen20
进行中（未招募）
不适用
Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal diseasePharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal diseaseMedDRA version: 9.1Level: LLTClassification code 10017533Term: Fungal infectionMedDRA version: 12.1Level: HLGTClassification code 10024324Term: LeukaemiasEUCTR2010-018752-27-NLRadboud University Nijmegen Medical Centre
已完成
2 期
Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal diseasefungal infectionhematology patients10017528NL-OMON34306niversitair Medisch Centrum Sint Radboud20
进行中（未招募）
不适用
Farmacocinética de anidulafungina en pacientes sometidos a hemodiafiltración.Tratamiento de candidiasis Invasiva en paciente adulto no neutropenico.MedDRA version: 13Level: LLTClassification code 10042938EUCTR2010-024457-36-ESDr.Gerardo Aguilar Dr.Francisco Martí Hospital Clínico de Valencia Ser. Anestesiología y Reanimación